What compounds target ERBB4?

BiohacksAI has identified 36 compounds that interact with ERBB4 (erb-b2 receptor tyrosine kinase 4). Top compounds include: gefitinib, erlotinib, sb 203580, ibrutinib, lapatinib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is ERBB4 (erb-b2 receptor tyrosine)?

ERBB4 is erb-b2 receptor tyrosine kinase 4. It is a molecular target for 36 compounds documented in PubMed bioassay data. UniProt ID: Q15303. NCBI Gene ID: 2066.

ERBB4

MOLECULAR TARGET

erb-b2 receptor tyrosine kinase 4

UniProt: Q15303 NCBI Gene: 206636 compounds

ERBB4 (erb-b2 receptor tyrosine kinase 4) is targeted by 36 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting ERBB4

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	gefitinib	5.67	290
2	erlotinib	5.55	256
3	sb 203580	4.92	136
4	ibrutinib	4.86	128
5	lapatinib	4.84	126
6	alvocidib	4.52	91
7	foretinib	4.34	76
8	vandetanib	4.30	73
9	bosutinib	4.08	58
10	bi 2536	4.01	54
11	midostaurin	3.85	46
12	brigatinib	3.81	44
13	neratinib	3.66	38
14	canertinib	3.53	33
15	pelitinib	3.50	32
16	tae 684	3.43	30
17	fedratinib	3.40	29
18	acalabrutinib	3.22	24
19	dacomitinib anhydrous	3.14	22
20	lestaurtinib	3.04	20
21	defosbarasertib	2.89	17
22	r 406	2.83	16
23	cediranib	2.83	16
24	ritlecitinib	2.77	15
25	zanubrutinib	2.56	12
26	evobrutinib	2.48	11
27	tak 285	2.40	10
28	tg100 115	2.08	7
29	canertinib dihydrochloride	2.08	7
30	tirabrutinib	1.95	6
31	varlitinib	1.79	5
32	ac 480	1.79	5
33	Afatinib	1.39	3
34	Dasatinib	1.10	2
35	sp600125	0.69	1
36	tyrphostin ag 1478	0.69	1

About ERBB4 as a Drug Target

ERBB4 (erb-b2 receptor tyrosine kinase 4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 36 compounds with documented ERBB4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

ERBB4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.